Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
2007 Standout
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
2017
CD73-Deficient Mice Are Resistant to Carcinogenesis
2012
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
2011
A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments
2009
Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells
2008
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
1998
Immunotherapy of cancer in 2012
2012
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
2017
Systemic effects of local radiotherapy
2009
T cell defined tumor antigens
1997
Cell Death Mechanisms and the Immune System
1991
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
2011 Nature
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues
2007
Combination cancer immunotherapy and new immunomodulatory targets
2015
Extracellular adenosine triphosphate and adenosine in cancer
2010
C-type lectins in immunity and homeostasis
2018
Chemotherapy induces ATP release from tumor cells
2009
Yeasts encoding tumour antigens in cancer immunotherapy
2005
Cancer despite immunosurveillance: immunoselection and immunosubversion
2006
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
2012
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Tumor immunoediting and immunosculpting pathways to cancer progression
2007
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
2014
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
2009
Purinergic regulation of the immune system
2016
Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
2017
Targeted Deletion of HIF-1α Gene in T Cells Prevents their Inhibition in Hypoxic Inflamed Tissues and Improves Septic Mice Survival
2007
CD73: a potent suppressor of antitumor immune responses
2012
The confluence of radiotherapy and immunotherapy
2012
Towards patient‐specific tumor antigen selection for vaccination
2002
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
2008
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
2011
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer
2013
Cancer vaccines: between the idea and the reality
2003
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
2015
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules
2001
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
2006
Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes
1993
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Adenosine, an endogenous distress signal, modulates tissue damage and repair
2007
Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences
2013
Therapeutic vaccines for cancer: an overview of clinical trials
2014
Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor
2015
Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
1996
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
Neutrophils in cancer: neutral no more
2016 Standout
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
1996 Standout
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
History of myeloid-derived suppressor cells
2013
Cancer-related inflammation
2008 StandoutNature
Adoptive-cell-transfer therapy for the treatment of patients with cancer
2003
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
2016 Standout
Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
2015
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice
2002 StandoutNobel
Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer
2012
Interleukin-10 and the immune response against cancer: a counterpoint
2005
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Current Developments in Cancer Vaccines and Cellular Immunotherapy
2003
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 high regulatory T cells in humans
2015 StandoutNobel
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
2015
CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
1998 StandoutNobel
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
2007
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis
2014
Manipulation of costimulatory signals to enhance antitumor T-cell responses
1995 StandoutNobel
Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides
2002
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Immunological mechanisms of the antitumor effects of supplemental oxygenation
2015
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
2011
Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles
1997 StandoutNobel
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Alphavirus-based expression vectors: strategies and applications.
1996 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
2010
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
2013
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Seppuku and Autoimmunity
1992 StandoutScienceNobel
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
2011
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis
2013
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
1998 StandoutNobel
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
2001
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
2000
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils
2015
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
2016
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
2014
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
2014
Enhancement of Antitumor Immunity by CTLA-4 Blockade
1996 StandoutScienceNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
1995
Current status of immunotherapy for the treatment of lung cancer.
2010
Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses
2000
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Phase I Study in Cancer Patients of a Replication-Defective Avipox Recombinant Vaccine That Expresses Human Carcinoembryonic Antigen
1999
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
2013
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
1996
A sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expressionin vivo
1995
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
1999
Works of Scott I. Abrams being referenced
A2A adenosine receptor protects tumors from antitumor T cells
2006
Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature
2013
Altered Immune Function during Long-Term Host-Tumor Interactions Can Be Modulated to Retard Autochthonous Neoplastic Growth
2007
Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21
1995
Sensitivity of T cells to anti‐CD3‐stimulated suicide is independent of functional phenotype
1992
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer
1996
Generation of Stable CD4+and CD8+T Cell Lines from Patients Immunized withrasOncogene-Derived Peptides Reflecting Codon 12 Mutations
1997
A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors
1999
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
2014
Tumor-Derived G-CSF Facilitates Neoplastic Growth through a Granulocytic Myeloid-Derived Suppressor Cell-Dependent Mechanism
2011
Rational antigen modification as a strategy to upregulate or downregulate antigen recognition
2000
Persistence, Immune Specificity, and Functional Ability of Murine Mutant Ras Epitope-Specific CD4+ and CD8+ T Lymphocytes Following in Vivo Adoptive Transfer
1999
Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine
1992
Detachment and Lysis of Adherent Target Cells by CD4+ T Cell Clones Involve Multiple Effector Mechanisms
1993
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses
1996
Deregulation of Apoptotic Factors Bcl-xL and Bax Confers Apoptotic Resistance to Myeloid-derived Suppressor Cells and Contributes to Their Persistence in Cancer
2013
Cancer Vaccines: Preclinical Studies and Novel Strategies
2006
Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8 + cytotoxic T lymphocytes
2001
Interferon regulatory factor‐8 modulates the development of tumour‐induced CD11b+Gr‐1+ myeloid cells
2009
Regulation of Tumor Progression by Anti-Neoplastic T Cell Responses
2004
How tumours escape mass destruction
2008
Identification of a ras Oncogene Peptide That Contains Both CD4+ and CD8+ T Cell Epitopes in a Nested Configuration and Elicits Both T Cell Subset Responses by Peptide or DNA Immunization
2000
Cytotoxic T lymphocyte-induced loss of target cell adhesion and lysis involve common and separate signaling pathways.
1989
Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-γ-Regulated Gene Expression
2005
Tumor-Induced STAT3 Signaling in Myeloid Cells Impairs Dendritic Cell Generation by Decreasing PKCβII Abundance
2014
External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing
2004
Role of anti-CTLA-4 therapies in the treatment of cancer.
2004
CD4+ T lymphocyte-induced target cell detachment. A model for T cell-mediated lytic and nonlytic inflammatory processes
1991
Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
1992
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
1994
Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy
2003
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
1994
Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
2016
Mutant ras epitopes as targets for cancer vaccines.
1996
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
2013
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
1995
CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape
2006